Glycopeptide Antibiotics Market Report 2025

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.54 billion in 2024 to $3.82 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.5 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, R&D investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.

The increasing incidence of cancer and infectious diseases is anticipated to drive the growth of the glycopeptide antibiotics market in the coming years. Cancer is a disease characterized by the uncontrolled multiplication of specific body cells that can spread to other regions, while infectious diseases are ailments caused by organisms such as bacteria, viruses, fungi, or parasites. Glycopeptide antibiotics are utilized to treat various infectious disorders resulting from methicillin-resistant Staphylococcus aureus, Streptococcus, or Enterococcus bacteria that are resistant to beta-lactams and other antibiotic classes. In cancer patients, glycopeptide antibiotics help enhance the antitumor effects of radiotherapy by targeting not only the primary cancer cells but also metastatic cells located further in the body. For example, the American Cancer Society, a US-based non-profit organization dedicated to cancer elimination, reported that in 2022, there were 1.9 million new cancer cases and 609,360 cancer-related deaths in the US, averaging 1,670 fatalities per day. Consequently, the rising cases of cancer and infectious diseases are expected to propel the growth of the glycopeptide antibiotics market.

The growing incidence of gram-positive infections is likely to drive the glycopeptide antibiotic market's expansion in the coming years. Gram-positive infections are caused by gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, among others. Glycopeptide antibiotics are particularly effective against numerous gram-positive bacteria due to their unique mechanism, which disrupts bacterial cell wall formation. For instance, the November 2023 report from the English Surveillance Programme for Antimicrobial Utilization and Resistance (ESPAUR) by the UK Health Security Agency, a governmental body responsible for public health and infectious disease protection in England, noted a 248% increase in infections from Group A Streptococcus (iGAS) in 2022 compared to 2021. Additionally, there were 21% more iGAS cases recorded in 2022 compared to three years prior, highlighting the rising prevalence of gram-positive infections and its impact on the glycopeptide antibiotic market.

Product innovation is a significant trend gaining traction in the glycopeptide antibiotics market. Key players in this sector are concentrating on developing groundbreaking products to enhance their market positions. For example, in October 2022, Leiden University, a research institution in the Netherlands, discovered new variants of the antibiotic vancomycin. This new variant was created by attaching a group of molecules to the existing structure of vancomycin. The result is a variant that is up to a thousand times more effective against gram-positive bacteria compared to the original vancomycin and exhibits lower nephrotoxicity than commercially available polymyxin antibiotics. This innovation addresses the limitation of vancomycin, which is effective only against gram-positive strains and cannot penetrate the outer membrane of gram-negative bacteria.

Leading companies in the glycopeptide antibiotics market are pursuing strategic partnerships to introduce life-saving revolutionary antibiotics in the Middle East. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. For instance, in March 2022, Cumberland Pharmaceuticals Inc., a US-based specialty pharmaceutical firm, announced a partnership with Tabuk Pharmaceutical Manufacturing Company. This agreement grants Tabuk exclusive trademark rights to promote the Vibativ (telavancin) injection for patients in Saudi Arabia, Jordan, and potentially other Middle Eastern countries. Vibativ is a crucial medication for patients suffering from ventilator-associated pneumonia and hospital-acquired pneumonia caused by various gram-positive bacterial infections, including those that are challenging to treat and multidrug-resistant. Tabuk Pharmaceutical Manufacturing Company is a pharmaceutical firm based in Saudi Arabia.

In January 2023, Fairlong Capital LLC, a US-based investment firm, acquired DoseMeRx for an undisclosed sum. This acquisition aims to enhance Fairlong Capital's precision dosing capabilities and improve patient outcomes through advanced medication management solutions. This strategic move allows the company to utilize innovative technology for more effective healthcare delivery. DoseMeRx is a US-based Bayesian dosing platform that optimizes dosing for glycopeptide antibiotics, such as vancomycin, by personalizing treatment based on individual patient factors.

Major companies operating in the glycopeptide antibiotics market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

North America was the largest region in the glycopeptide antibiotics market in 2024. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Glycopeptide antibiotics constitute a category of antibiotics characterized by structures that include a glycosylated cyclic or polycyclic non-ribosomal peptide, and they are employed to impede the formation of bacterial cell walls. These antibiotics were initially discovered in plant and soil bacteria.

The primary drugs within the glycopeptide antibiotics class include vancomycin, dalbavancin, oritavancin, and others. Vancomycin, for example, is a member of the glycopeptide antibiotics family, recognized for its ability to eliminate microorganisms in the intestines. It is used in the treatment of colitis, a condition that can develop after antibiotic therapy. These drugs are administered through oral, parenteral, and other routes for the treatment of various conditions such as skin and structure infections, meningitis, Clostridioides difficile infection, enterocolitis, and more. The end-users of these antibiotics include hospitals, specialty clinics, home care, and other healthcare providers.

The glycopeptide antibiotics market research report is one of a series of new reports that provides glycopeptide antibiotics market statistics, including glycopeptide antibiotics industry global market size, regional shares, competitors with a glycopeptide antibiotics market share, detailed glycopeptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. This glycopeptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.